International Association for the Study of Lung Cancer: Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study
September 09, 2024
September 09, 2024
AURORA, Colorado, Sept. 9 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release on Sept. 8, 2024:
(San Diego, Calif--September 8, 2024, 8:30 a.m.) -- Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented tod . . .
(San Diego, Calif--September 8, 2024, 8:30 a.m.) -- Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented tod . . .